[go: up one dir, main page]

WO1982001867A1 - Compose pharmaceutique et procede - Google Patents

Compose pharmaceutique et procede Download PDF

Info

Publication number
WO1982001867A1
WO1982001867A1 PCT/AU1981/000164 AU8100164W WO8201867A1 WO 1982001867 A1 WO1982001867 A1 WO 1982001867A1 AU 8100164 W AU8100164 W AU 8100164W WO 8201867 A1 WO8201867 A1 WO 8201867A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycerol
zinc
pharmaceutical compound
temperature
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU1981/000164
Other languages
English (en)
Inventor
Alan J Brock
Reginald M Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE813152555T priority Critical patent/DE3152555T1/de
Publication of WO1982001867A1 publication Critical patent/WO1982001867A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/68—Preparation of metal alcoholates
    • C07C29/70—Preparation of metal alcoholates by converting hydroxy groups to O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/28—Metal alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00—Preparations for removing hair or for aiding hair removal
    • A61Q9/02—Shaving preparations

Definitions

  • This invention relates to certain pharmaceutical compounds and to their use for therapeutic and prophylactic treatment of the human body and for veterinary purposes.
  • the invention relates to use of metal glycerolate compounds as a base for
  • metal zinc is necessary in trace element form for cell division and tissue repair and also in-various compounds has a knovn slight bactericidal and fungicidal action on the
  • Crystalline glycerato-metal complexes were first described in a paper in the Australian Journal of Chemistry volume 23, 1970, Page 1,963 and in that paper the method of forming these compounds and some of their physical properties are given. These compounds form during the heating of particular metal oxides, hydroxides or salts with glycerol at temperatures around 120° or higher.
  • the physical structure of the resulting chelated compounds generally produces a platy morphology resulting in a talc-like or slippery tactile impression.
  • glycerato-metal complexes can be arranged to give valuable advantage in the treatment of various medical disorders, and extends to a method of treatment of skin disorders comprising the step of applying to the affected skin a modified zinc glycerolate complex including a pharmaceutically acceptable carrier or extender, or the compound may be" used as a barrier substance or a sun screen or as a protective surface of high lubricity when applied to the skin.
  • OMPI IPO subsequently chemically altered by certain reagents to achieve a composition which may recommend its use because of specific effects in particular topical skin application whether for therapeutic or cosmetic purposes while maintaining the advantageous physical properties.
  • any zinc salt or compound which decomposes to ZnO on heating at temperatures between approximately 120-300°C will form this compound.
  • the heating of zinc acetate and glycerol forms a zinc glycerolate complex via a solution phase.
  • OMPI variation in size of the relatively thin platlets so that smaller crystals fit into the spaces between larger crystals and provide a highly successful protective screen.
  • FIG. 1 herein shows a drawing taken from a photograph of crystals of zinc glycerolate, using a magnification of 9000, and
  • FIG. 2 shows one of the crystals, illustrating their plate-like nature, the photograph of that crystal having a magnification of 18,000.
  • FIG. 1 shows a large crystal 1 with medium sized crystals 2 and a range of sizes down to the smaller crystals 3, all however retaining thei ⁇ characteristic of elongated hexagonal configuration with relatively low thickness .
  • crystals can beproduced from either zinc oxide or zinc acetate when reacted with glycerol, but preferably zinc oxide is the medium used in that it produces the platlets illustrated, whereas the product formed by precipitation from the solution phase of zinc acetate in heated glycerol may exhibit additional particles the shape and size of which may detract from the overall lubricity.
  • the zinc glycerolate appears to conform to the general formulae C HgO ⁇ Zn and the complex is most suitably formed from the high temperature heating with vigorous stirring of zinc oxide in glycerol.
  • zinc acetate can be used as this dissolves in the hot glycerol and the precipitate formed is the desired product.
  • vigorous stirring is needed to produce a small general particle size product with a preferable variation in crystal size and a talc-like, but non-greasy feel.
  • the mixture should be kept at about 260°C for about 1 hour to ensure reaction has gone to completion.
  • the increased viscosity is noted in the tem- perature range 195-220°C.
  • the material can be heated for longer than one hour at the maximum temperature if residual zinc oxide is still present.
  • the suspension, of the complex in the excess glycerol can be diluted with ethanol and this can be distilled off during the next process before further zinc oxide is added and the process repeated.
  • the theoretical zinc content on dried product is 42.06%.
  • OMPI was 86 gms or 90% (theoretical yield: 95.45gms).
  • the I.R. was identical to literature values.
  • Assay Zn content actual 43.56% (theoretical 42.06%).
  • the glycerol was heated to 120°C with stirring.
  • Zinc oxide 50g, 0.614 moles was added at this temperature to form a well dispersed suspension.
  • the mixture was then slowly heated with vigorous stirring to 260 C. During the heating process, two changes in viscosity were noted. The first was a thickening of the reaction mixture to an almost paste consistency, then upon further heating the reaction mixture became less viscous.
  • the crystals produced by this method consisted of a mixture of small hexagonal plates ( ⁇ lO microns) and elongated crystals.
  • Example 2 As per Example 1 except zinc acetate (50gms, 0.23 moles . ) was used instead of zinc oxide.
  • the product zinc glycerolate was isolated as above in 85% yield.
  • the particle size varied from 10-70 microns, while the crystals were a mixture of elongated filament clusters and platlet structures.
  • the high insolubility of zinc glycerolate in water and organic solvents means that crystals cannot be obtained by growth from solution.
  • zinc glycerolate is related in part to its small but varying crystal size and crystal shape, the product produced by the reaction of zinc acetate and glycerol producing larger crystals than the reaction of zinc oxide with the latter.
  • OMPI or prophylactic treatments other substances can be added as an admixture or as a means of producing further reaction products, and for example an aqueous solution of a copper salt may be added to the zinc glycerolate to replace small amounts of zinc in the complex by copper, resulting in a colour change and the ability to bring trace amounts of copper into contact with the skin when used as an ointment.
  • aqueous solution of a copper salt may be added to the zinc glycerolate to replace small amounts of zinc in the complex by copper, resulting in a colour change and the ability to bring trace amounts of copper into contact with the skin when used as an ointment.
  • EXAMPLE 5 A weak neutral solution of cupric chloride was shaken with a little zinc glycerolate, the mixture was filtered through a Buchner funnel and the residue washed in turn with alcohol and acetone. The product so formed was blue in colour.
  • a further example may be given by the chemical absorption of suitable dyes by the zinc glycerolate giving a resultant obvious or non-obvious coloration when applied to the skin without destruction of the lubricity, or tactile qualities that make the original zinc compound advantageous for particular applications .
  • Zinc glycerolate which was tan in colour was obtained by the addition of certolake erythrosine (O.lg) and certolake tartrazine (0.4g) to zinc oxide (40g) prior to reaction with glycerol in the manner described in Example 1.
  • zinc glycerolate as a topical application is not limited to its combination with metal cations or dye-stuffs given in the examples
  • OMPI IPO various skin disorders arising out of exposure to sunlight, while presenting properties of a non- apparent topical application.
  • the zinc glycerolate complex has been found to be effective in the treatment and prevention of a ⁇ moniacal dermatitis (burns in the genital areas of babies which originate from ammonia liberated during the de ⁇ composition of urine - nappy rash) , in the treatment of pruritus, especially in people confined to bed or immobility, for the alleviation of psoriasis, for the treatment and prevention of fungal or bacteriacidal decomposition of tissue and the resultant odours arising in such complaints as tinea pedis and for the prevention of industrial dermatitus arising from particular environments. It is also envisaged that the properties of this compound would make it effective in the treatment of ichthyosis.
  • This invention is not restricted to the use of zinc glycerolate in only the above therapeutic and prophylactic applications but it embraces all other use of this compound when reacted or blended with other therapeutic substances.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compose pharmaceutique ayant des proprietes therapeutiques, prophylactiques et cosmetiques a usages humain et veterinaire, est un complexe de glycerolate de zinc forme comme un produit de reaction d'oxyde de zinc et de glycerol, platymorphologique avec des cristaux hexagonaux (1/2/3) ayant une epaisseur relativement faible et un grand pouvoir lubrifiant, avec ou sans d'autres produits de reaction ou porteurs.
PCT/AU1981/000164 1980-11-24 1981-11-18 Compose pharmaceutique et procede Ceased WO1982001867A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE813152555T DE3152555T1 (de) 1980-11-24 1981-11-18 Pharmaceutical compound and method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPE660280 1980-11-24
AU6602/80 1980-11-24
AUPF017681 1981-08-11
AU176/81810811 1981-08-11

Publications (1)

Publication Number Publication Date
WO1982001867A1 true WO1982001867A1 (fr) 1982-06-10

Family

ID=25642428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1981/000164 Ceased WO1982001867A1 (fr) 1980-11-24 1981-11-18 Compose pharmaceutique et procede

Country Status (5)

Country Link
JP (1) JPH0256337B2 (fr)
DE (1) DE3152555T1 (fr)
FR (1) FR2494583B1 (fr)
GB (1) GB2101132B (fr)
WO (1) WO1982001867A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3913194A1 (de) * 1988-04-22 1989-11-02 Medvet Science Pty Ltd Entzuendunshemmende oder reizmildernde zinksalzzubereitung
GB2191941B (en) * 1985-08-27 1990-03-14 Glyzinc Pharma Ltd Zinc glycerolate complex and additions for pharmaceutical applications
WO1994002131A1 (fr) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Traitement de maladies herpetiques
WO1994002132A1 (fr) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Traitement de maladies de la peau
WO1994028884A1 (fr) * 1993-06-15 1994-12-22 Glyzinc Pharmaceuticals Limited Complexe de monoglycerolate de zinc destine a un traitement anti-rejet du corps humain ou animal
WO1995008524A1 (fr) * 1993-09-23 1995-03-30 Pharmaserve Limited Production de glycerolate de zinc
US11969734B2 (en) 2018-05-29 2024-04-30 Deasyl Sa Three-dimensional grinder, method for implementing same and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005035A1 (fr) * 1986-12-30 1988-07-14 Hallsworth & Associates Pty. Limited Ameliorations apportees a la formation d'alkoxydes de metal et de poudres de metal par utilisation d'un rayonnement a micro-ondes
JP6065520B2 (ja) * 2012-10-24 2017-01-25 堺化学工業株式会社 酸化亜鉛粒子の製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996346A (en) * 1975-03-18 1976-12-07 Dominic Thomas Staffier Composition for reducing bodily odor and perspiration
US4160821A (en) * 1978-02-27 1979-07-10 Johnson & Johnson Treatment for gingivitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996346A (en) * 1975-03-18 1976-12-07 Dominic Thomas Staffier Composition for reducing bodily odor and perspiration
US4160821A (en) * 1978-02-27 1979-07-10 Johnson & Johnson Treatment for gingivitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAYLOR et al: "AUSTRALIAN JOURNAL of CHEMISTRY, 1970, 23, 1963-71 (CSIRO, MELBOURNE) *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2191941B (en) * 1985-08-27 1990-03-14 Glyzinc Pharma Ltd Zinc glycerolate complex and additions for pharmaceutical applications
DE3913194A1 (de) * 1988-04-22 1989-11-02 Medvet Science Pty Ltd Entzuendunshemmende oder reizmildernde zinksalzzubereitung
WO1994002131A1 (fr) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Traitement de maladies herpetiques
WO1994002132A1 (fr) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Traitement de maladies de la peau
WO1994002133A1 (fr) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Traitement de brulures
WO1994028884A1 (fr) * 1993-06-15 1994-12-22 Glyzinc Pharmaceuticals Limited Complexe de monoglycerolate de zinc destine a un traitement anti-rejet du corps humain ou animal
WO1995008524A1 (fr) * 1993-09-23 1995-03-30 Pharmaserve Limited Production de glycerolate de zinc
US11969734B2 (en) 2018-05-29 2024-04-30 Deasyl Sa Three-dimensional grinder, method for implementing same and uses thereof

Also Published As

Publication number Publication date
FR2494583B1 (fr) 1985-10-11
JPS57501783A (fr) 1982-10-07
DE3152555T1 (de) 1982-12-02
DE3152555C2 (fr) 1991-01-03
GB2101132A (en) 1983-01-12
GB2101132B (en) 1985-05-15
JPH0256337B2 (fr) 1990-11-29
FR2494583A1 (fr) 1982-05-28

Similar Documents

Publication Publication Date Title
AU554151B2 (en) Pharmaceutical compound and method
DE69213159T2 (de) Addukte von ton und aktivierten gemischten metalloxyden
EP0904768B1 (fr) Matériau composite particulaire à base de silice et d'oxyde métallique et procédé de préparation du même
DE2327087C3 (fr)
WO1982001867A1 (fr) Compose pharmaceutique et procede
US5718908A (en) Topical formulations based on mineral gels
DE3932377C2 (fr)
JPH02251240A (ja) 紫外線吸収剤内包マイクロカプセル及びその製造方法並びにそのマイクロカプセルを含有する化粧料
DE60012151T2 (de) Deodorantzusammensetzungen
DE4134540A1 (de) Desinfizierende keramikzusammensetzung
US2761867A (en) Aluminum salts of allantoin and their preparation and compositions comprising the same
DE2857424C2 (fr)
JPS63250309A (ja) 抗菌剤
CH638676A5 (de) Karies verhinderndes mittel.
JP2608786B2 (ja) 粉末化粧料
US2177197A (en) Composition of matter
DE2514878B2 (de) Allantoin-ascorbinsaeure-komplexe
JPH0458443B2 (fr)
JPH05194174A (ja) 化粧用顔料およびその製造方法ならびに化粧料
US2407247A (en) Bonded adsorbent
JPH0543682B2 (fr)
JPH06104609B2 (ja) 化粧料
JP2746922B2 (ja) 入浴剤
JP2865380B2 (ja) 抗菌性化粧料
JP2963133B2 (ja) 抗菌性アパタイト

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DE GB JP US

RET De translation (de og part 6b)

Ref document number: 3152555

Country of ref document: DE

Date of ref document: 19821202

WWE Wipo information: entry into national phase

Ref document number: 3152555

Country of ref document: DE